Congratulations to the team of our portfolio company TargED Biopharmaceuticals, as they have been awarded a Take-Off 2 grant from NWO (the Dutch National Science Organization)!
TargED closes seed investment and partners with UMC Utrecht for the development of Microlyse – a next-generation thrombolytic clot-busting drug
We’re thrilled to announce UHSF’s first investment, in TargED Biopharmaceuticals, together with Curie Capital and FIRST Fund. TargED is developing a next generation clot-busting drug with unique properties, initially focusing on acute ischemic stroke as its target, with several thrombotic diseases as potential spin-offs. Please find the press release below: TargED closes seed
The Regional Development Fund (Regionale Ontwikkelingsmaatschappij or ROM) for the region of Utrecht is launched. The ROM Regio Utrecht Fund aims to strengthen the economic structure and innovation power of the Utrecht region. We at the Utrecht Health Seed Fund (UHSF) look forward to collaborating with the ROM in the
The Utrecht Health Seed Fund (UHSF) officially launched at the end of March. Over the next three years, it’ll be looking to invest in promising start-ups based in the province of Utrecht and working in the field of Life Sciences & Health (LS&H). Jaap de Bruin (UHSF Fund Manager) explains the reasons for setting up the UHSF, “Utrecht is
March 24, 2020 a new investment fund starts – the Utrecht Health Seed Fund (UHSF). The goal is to invest a total of €5.4 million in promising start-ups located in the province of Utrecht that are developing scalable technologies in the field of Life Sciences & Health: Life Sciences (biotech, pharmaceuticals
The Utrecht Health Seed Fund (UHSF) is a joint initiative established by Utrecht Holdings and the Economic Board Utrecht (EBU) with the assistance and support of the European Regional Development Fund (ERDF), University Medical Center Utrecht, and the University of Utrecht.